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ORIGINAL ARTICLE

Impact of vitamin D supplementation on adiposity in
African-Americans
PD Chandler1,2, JB Scott3, BF Drake4, K Ng2,5, AT Chan2,6, BW Hollis7, KM Emmons2,8, EL Giovannucci2,9,10, CS Fuchs2,5 and GG Bennett11
BACKGROUND: African-Americans have higher rates of obesity-associated chronic diseases. Serum 25-hydroxyvitamin D (25(OH)D)
shows an inverse association with obesity status. We investigated whether vitamin D supplementation changes body mass
index (BMI).
SUBJECTS: In total, 328 overweight African-Americans were enrolled over three consecutive winter periods (2007–2010) into a
randomized, double-blind, placebo-controlled trial to receive cholecalciferol supplementation (0, 1000 international units (IU),
2000 IU or 4000 IU per day) for 3 months. Plasma concentrations of 25(OH)D and anthropometric measurements were done at
baseline, 3 and 6 months.
RESULTS: At 3 months, vitamin D supplementation in three dose groups (1000 IU, 2000 IU or 4000 IU per day) did not cause any
signiﬁcant changes in BMI as compared with placebo group 3-month change in BMI per 1000 IU per day estimate (SE): 0.01 (0.039);
P = 0.78.
CONCLUSIONS: In overweight African-Americans, short-term high-dose vitamin D supplementation did not alter BMI.
Nutrition & Diabetes (2015) 5, e147; doi:10.1038/nutd.2014.44; published online 19 January 2015

INTRODUCTION
An urgent need exists to identify modiﬁable dietary risk factors for
obesity in African-Americans. Human observations since the
1980’s of lower levels of 25-hydroxyvitamin D25(OH)D in obese
than in nonobese individuals highlight a possible inverse relation
between vitamin D and obesity.1
African-Americans have consistent associations of vitamin D
deﬁciency with obesity and obesity-associated chronic
diseases, such as hypertension, coronary heart disease, diabetes
and certain cancers,2 although of potentially lower magnitude
than Whites.3,4 Furthermore, African-Americans have lower
vitamin D and calcium dietary intake.5 The mechanisms underlying this association may include a role for 25(OH)D in regulating
lipid metabolism in adipose cells. In vivo studies suggest that
vitamin D and calcium administration increase fatty-acid oxidation
and decrease lipogenesis.6,7
Results from clinical trials measuring the effect of vitamin D
supplementation on obesity are limited and mixed. Some trials
show no association of vitamin D supplementation with weight
loss.8–10 Other trials show that vitamin D supplementation
may be signiﬁcantly associated with less weight gain but
that this association may be dependent on adjunctive calcium
supplementation and a particular region of fat.11,12 A recent metaanalysis showed no signiﬁcant effect of vitamin D supplementation on body mass index (BMI), weight or other adiposity
measures.13 This meta-analysis did not assess potential ethnic/
racial differences in the effect of vitamin D supplementation on
adiposity measures. Studies evaluating the effect of vitamin D

supplementation on measures such as insulin resistance in
African-Americans14 have not reported on changes in adiposity
measures. Thus, this ancillary analysis was undertaken to test the
hypothesis that supplementation with vitamin D3 (cholecalciferol)
leads to weight loss in African-Americans.
MATERIALS AND METHODS
Study design and participants
This is a prospective, randomized, double-blind, placebo-controlled clinical
trial of oral cholecalciferol (vitamin D3) in a community-based overweight
African-American population (ClinicalTrials.gov NCT00585637). The protocol has been described in detail elsewhere.15 The primary goal of the trial
was to examine the effect of daily supplementation of 1000 international
units (IU) of vitamin D3, 2000 IU of vitamin D3 and 4000 IU of vitamin D3
and placebo on plasma 25(OH)D levels. All participants provided written
informed consent. This trial focused on African-Americans because AfricanAmericans have higher rates of vitamin D deﬁciency compared with
Whites5 or Africans.16 The project was approved by the Institutional Review
Boards of Harvard School of Public Health and Dana-Farber Cancer
Institute. All procedures were followed in accordance with institutional
guidelines.
Recruitment and randomization. Participants in Open Doors to Health, a
colorectal cancer prevention intervention study conducted in 12 public
housing communities in the Boston metropolitan area,17 were invited to
participate if they were 30–80 years old, understood written and spoken
English, self-identiﬁed as Black18–20 and had permission from their primary
care doctors. We also recruited participants from community and faithbased organizations and refer-a-friend program. A total of 328 individuals
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indistinguishable, and both participants and research staff were blinded to
treatment assignment. Study medications were started in early winter
(November or December) and were taken orally once daily for 3 months
(completed in February or March).

were enrolled into the parent trial (Figure 1). Exclusion criteria included
pregnancy, renal disease, pre-existing parathyroid, thyroid, or calcium
metabolism disorders, sarcoidosis, requirement for calcium channel
blockers, type I diabetes and active malignancies (other than nonmelanoma skin cancer). Those taking vitamin D supplementation were
enrolled if they agreed to discontinue these medications for 6 months
prior to enrollment and during the study.

Compliance and safety. All participants were assessed for adverse events
by study staff over the phone at week 2 of each month and in-person at
the beginning of each month when the next month’s supply of vitamins
was provided. Participants were educated on the warning signs and
symptoms of hypercalcemia. Serum calcium was measured in subjects
taking hydrochlorothiazide at 1 and 3 months. An additional subset of
44 ‘control’ participants not taking hydrochlorothiazide also underwent
calcium assays at 3 months. Electronic pill dispenser systems and pill
counts were used to track compliance with study supplementation in
addition to biweekly phone calls. Any subject found to have calcium

Treatment. Participants were assigned to four arms consisting of placebo,
1000 IU per day, 2000 IU per day or 4000 IU per day of vitamin D3 for
3 months in a 1:1:1:1 ratio using block randomization stratiﬁed by age, sex
and enrollment month. Study statisticians generated the random
allocation sequence and subjects were enrolled by research assistants.
All capsules also contained 200 mg of calcium carbonate (Pharmavite LLC,
Mission Hill, CA, USA). Calcium was included because prior studies have
shown that African-Americans have low calcium intake.21 All capsules were

Participants
consented
(n=576)

Ineligible by primary care physician
(n=126)

Eligible, but primary care physician refused
(n=84)

Eligible by
primary care
physician (n=366)

Lost to follow-up (n=7)
Refused (n=31)

Participants
randomized
(n=328)

Placebo
(n=81)

Vitamin D3
1,000 IU/day
(n=81)

Vitamin D3
2,000 IU/day
(n=83)

Vitamin D3
4,000 IU/day
(n=83)

Lost to follow-up (n=11)
Withdrawal (n=20)
Adverse event (n=4)

Lost to follow-up (n=15)
Withdrawal (n=21)

Participants who
completed 3-month
assessment
(n=293)

Placebo
(n=71)

Vitamin D3
1,000 IU/day
(n=67)

Vitamin D3
2,000 IU/day
(n=76)

Participants who
completed 6-month
assessment
(n=292)

Vitamin D3
4,000 IU/day
(n=78)

Placebo
(n=75)

Figure 1.

Consort diagram.
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42.62 mmol l− 1 (10.5 mg dl − 1) was immediately discontinued from the
study and the primary care physician was notiﬁed.
Measurement of 25(OH)D levels. Blood samples collected at baseline, 3
and 6 months were separated, and plasma was stored in liquid nitrogen in
the Dana-Farber Cancer Institute Clinical Research Laboratory (Boston, MA,
USA). Once study was completed, all plasma samples that were sent as a
single batch to the laboratory of Dr Bruce Hollis (Medical University of
South Carolina, Charleston, SC, USA) were 25(OH)D concentrations were
measured using the Diasorin (DiaSorin, Inc., Stillwater, MN, USA)
radioimmunoassay.22 Masked quality control samples were interspersed
among the cases and all laboratory personnel were blinded. The mean
coefﬁcient of variation of 25(OH)D measurements was 9%.

Anthropometric measurements
Weight was measured using electronic digital scales to the nearest 0.2 kg.
Height was measured using a wall-mounted stadiometer. BMI was
subsequently calculated as weight (kg) per height (m2).

Dietary measurements and physical activity
Dietary and calcium intake was assessed at baseline and at 3 months
with an abbreviated form of the semiquantitative Food Frequency
Questionnaire.23,24 The responses were recoded to equivalent servings
per week and summed to obtain total servings of calcium-rich food groups
and vitamin D-rich food groups per week. Dietary vitamin D per serving
included (100 IU for milk and soymilk; 400 IU for multivitamin or vitamin D
supplement, 100 IU for ice cream, 100 IU for yogurt, 560 IU for dark ﬁsh,
100 IU for fortiﬁed orange juice and 100 IU for cold cereal).

Statistical analysis
The primary end point for this study was the change in BMI and weight for
the participants from 0 to 3 months. We analyzed the change within each
dose group from month 0 to month 3 using linear regression. Statistical
power for this trial was based on the intent-to-treat population of 80
subjects per arm. Using a two-sided t-test at the 0.05 signiﬁcance level, the
minimum detectable difference in 25(OH)D between treatment arms was
13.2 and 15.5 nmol l − 1 (5.3 and 6.2 ng ml − 1) with 80% and 90% power,
respectively. We estimated that the minimum detectable difference in
weight between treatment arms was 4 kg and 6 kg with 80% and 90%
power, respectively. All statistical analyses were performed using SAS 9.2
(SAS Institute, Cary, NC, USA).

RESULTS
Subject characteristics according to supplementation arm
Baseline characteristics for the 328 randomized participants are
presented in Table 1. The participants had moderately active
lifestyles. Mean exercise frequency was 3 times per week.
Approximately 32 (9.8%), 24 (7.3%) and 65 (19.8%) participants
were taking supplemental calcium, vitamin D and multivitamin,
respectively, at baseline. Approximately 99 (30.2%) of the
participants were current smokers. More participants in the
placebo and 1000 IU per day arms had a past history of cancer
than those assigned to 2000 or 4000 IU per day. Otherwise, there
were no signiﬁcant differences in any of the subject characteristics
between the supplementation arms. Compliance was 96.6%
across the cohort.
Impact of vitamin D3 supplementation on plasma 25(OH)D
Among 328 subjects, 25(OH)D level at baseline was median
interquartile range (IQR):15.3 ng ml − 1 (12.5) with 25(OH)D 420
ng ml − 1 in 34.3% of participants. The effect of the various doses of
vitamin D3 supplementation on 25(OH)D levels after 3 months is
shown in Table 2. At 3 months, median 25(OH)D levels rose to
29.7, 34.8 and 45.9 ng ml − 1, respectively, in participants assigned
to 1000, 2000 and 4000 IU per day. After 3 months of vitamin D3
supplementation, 292 subjects (89%) provided plasma for followup 25(OH)D determination. The compliance rate with randomized
therapy in the whole cohort was 96.6%.
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Association of baseline 25(OH)D and BMI and weight
There was no signiﬁcant association between BMI or weight and
25(OH)D at the beginning of the study. Baseline weight and
baseline BMI were not signiﬁcantly associated with 25(OH)D
(estimate (SE), P-value: BMI, − 0.04 (0.07), P = 0.55; weight, − 0.02
(0.01), P = 0.06). Baseline 25(OH)D was not signiﬁcantly associated
with baseline BMI or baseline weight (BMI, − 0.03 (0.05), P = 0.55;
weight, − 0.56 (0.30), P = 0.06).
Impact of vitamin D supplementation on BMI and weight
The primary efﬁcacy analyses of vitamin D3 supplementation on
weight and BMI are shown in Table 2. In linear regression with the
dose of vitamin D3 (per 1000 IU per day) as the independent
variable and the 3-month change in weight (or 3-month change in
BMI) as the dependent variable, no effect of vitamin D3 on change
in BMI or weight was observed. For each additional 1000 IU
per day of vitamin D3, BMI increased by estimate (SE): 0.01(0.039);
P = 0.78 and weight increased by estimate (SE):0.06 (0.24); P = 0.81.
At 6 months, no signiﬁcant change in BMI or weight was observed
(Table 2).
Adverse events
There were ﬁve isolated incidences of mild hypercalcemia that
were in the reference range on repeated sampling. Vitamin D
supplements were discontinued in the four participants with mild
hypercalcemia at 1 month. Vitamin D supplementation was
discontinued in the participant who had hypercalcemia at
month 3. There were no episodes of nephrolithiasis.
DISCUSSION
On the basis of evidence showing that vitamin D deﬁciency is
associated with obesity, we tested the hypothesis that
vitamin D supplementation could reduce BMI in a randomized,
placebo-controlled trial of African-Americans. Although circulating
25(OH)D increased with vitamin D supplementation, we found
that vitamin D supplementation did not lower BMI or weight
among healthy African-Americans. Numerous cross-sectional
studies have assessed the relationship between vitamin D status
and different measures of adiposity.2 These studies found an
inverse relationship between vitamin D and total body fat and
regional adipose tissue.2 Others have shown an inverse relationship between vitamin D levels and components of metabolic
syndrome, including abdominal obesity,25 which is a known risk
factor for several chronic conditions. Furthermore, a recent metaanalysis evaluating the effect of vitamin D supplementation on
adiposity biomarkers in randomized controlled trials found no
signiﬁcant reduction in adiposity measures in the absence of
calorie restriction.13
The lack of effect of vitamin D supplementation on weight may
be due to low dietary calcium intake. Heaney et al.,26 concluded
that vitamin D status and beneﬁts associated with vitamin D
supplementation appear to be dependent on calcium intakes at or
above recommended amounts. The doses of vitamin D tested in
this study, as well as the dosing schedule (once per day, rather
than intermittent large boluses), may provide an optimal balance
of efﬁcacy and safety based on current evidence and the
recommended daily allowance and tolerable upper limit set by
the Institute of Medicine.27
Although there have been some trials including Whites that
suggest that vitamin D supplementation prevents weight gain or
promotes weight loss, little is known about African-Americans.28
Some have shown positive effects on weight but these effects
may have been due to the adjunctive calcium supplementation.
For example, in the Women’s Health Initiative Study,12 women
who were randomly assigned to calcium and vitamin D
Nutrition & Diabetes (2015) 1 – 7
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Table 1.

Baseline characteristicsa

Characteristic

P-valueb

Vitamin D3 dose assignment (IU per day)

Age, years, median (IQR)
Sex, No. (%)
Male
Female

Placebo

1000

2000

4000

(n = 81)

(n = 81)

(n = 83)

(n = 83)

50.7 (44.1–58.0)

51.1 (43.4–60.1)

50.3 (43.5–58.3)

51.3 (44.1–59.7)

0.98
0.72

27 (33.3)
54 (66.7)

BMI, kgm −2, median (IQR)
BMI o25 kg m−2, mean (s.d.)
No. (%)
BMI 25–29.9 kg m−2, mean (s.d.)
No. (%)
BMI 430 kg m−2, mean (s.d.)
25(OH)D o20 ng ml − 1, No. (%)
25(OHD) ng ml − 1, median (IQR)

31.2
20.8
11
27.0
25
37.1
53
15.1

Smoking status, No. (%)
Never
Past
Current

(26.5–35.9)
(2.2)
(13.5)
(1.1)
(30.8)
(5.9)
(65)
(10.4–23.6)

22 (27.2)
59 (72.8)
30.5
23.3
11
27.9
24
37.6
50
16.2

(27.0–37.5)
(1.4)
(13.5)
(1.5)
(29.6)
(5.8)
(62)
(11.0–22.7)

28 (33.7)
55 (66.3)
31.9
22.9
16
27.6
21
38.4
59
13.9

(26.2–36.9)
(1.4)
(19.2)
(1.5)
(25.3)
(6.2)
(71)
(9.5–22.3)

29 (34.9)
54 (65.1)
31.4
21.9
10
27.6
25
36.6
53
15.7

(27.4–35.7)
(3.1)
(8.3)
(1.5)
(30.1)
(5.6)
(64)
(11.0–23.3)

0.82

0.46
0.63
0.26

33 (40.7)
20 (24.7)
28 (34.6)

36 (44.4)
16 (19.8)
29 (35.8)

33 (39.8)
27 (32.5)
23 (27.7)

44 (53.0)
20 (24.1)
19 (22.9)

3.0 (0.5–5.0)
3.0 (1.0–5.0)
3.0 (0–5.0)
3.0 (0–5.0)
Frequency of exercise,c days per week, median (IQR)
Dietary vitamin D intake, median (IQR)
147.3 (71.4–262.8) 162.5 (92.6–295.5) 144.0 (58.0–265.1) 198.1 (83.2–306.4)
Dietary calcium intake, median (IQR)
264.6 (177.7–600.8) 419.4 (233.5–820.3) 314.4 (178.2–632.0) 425 (203.4–829.0)
10(12)
18(22)
15(18)
22(27)
Regular multivitamin use,d No. (%)
d
8(10)
6(8)
2(2)
8(10)
Regular vitamin D supplement use, No. (%)

0.99
0.41
0.11
0.16
0.45

Food, servings per week (median (IQR))
Milk
Soy milk
Cheese
Ice cream
Yogurt
Green leafy vegetables
Dark ﬁsh
Orange juice
Cold cereal

0.9
0.41
0.58
0.64
0.03
0.71
0.52
0.29
0.78

0.1 (0.1–0.3)
0
0.3 (0.1–0.3)
0.1 (0–0.1)
0 (0–0.1)
0.3 (0.1–0.6)
0.1 (0–0.3)
0.1 (0–0.3)
0.1 (0–0.3)

Post-menopausal hormone use, No. (%)
Yes
d

Regular calcium supplement use, No. (%)
Regular aspirin use,e No. (%)
Regular NSAID use,f No. (%)
Regular acetaminophen use, No. (%)e
Marital status, married, No. (%)
History of cancer, No. (%)g

0
7
4
6
6
23
6

(8.7)
(4.9)
(7.4)
(7.4)
(28.4)
(7.4)

0.1 (0.1–0.6)
0
0.3 (0.1–0.3)
0 (0–0.1)
0.1 (0–0.3)
0.3 (0.3–0.6)
0.1 (0–0.1)
0.1 (0–0.3)
0.1 (0–0.3)

0.3 (0.1–0.6)
0
0.3 (0.1–0.6)
0.1 (0–0.3)
0 (0–0.3)
0.3 (0.1–0.6)
0.1 (0–0.3)
0.1 (0–0.3)
0.1 (0–0.3)

0
9 (11.1)
10 (12.3)
10(12.3)
6 (7.4)
30 (37.0)
0

0
7
5
10
5
23
3

(8.4)
(6.0)
(12.0)
(6.0)
(27.7)
(3.6)

0.3 (0.1–0.6)
0
0.4 (0.1–0.6)
0.1 (0–0.3)
0.1 (0–0.3)
0.3 (0.3–0.6)
0.1 (0–0.3)
0.1 (0–0.6)
0.1 (0–0.3)
1 (0.5)

0.72

9(10.8)
8 (9.6)
7 (8.4)
5 (6.0)
24 (28.9)
15 (4.6)

0.49
0.23
0.73
0.96
0.58
0.032

Abbreviations: IU, international units; IQR, interquartile range; No., number; NSAID, non-steroidal anti-inﬂammatory drug. aData are No. (%) unless otherwise
indicated. The numbers do not always sum to group totals owing to missing information for some variables. 25(OH)D conversion to nmol l − 1 is 2.49 nmol l − 1
for each ng ml − 1. bThe Kruskal–Wallis test was used to calculate P-values for continuous variables. All statistical tests are two-sided. cExercise deﬁned as
moderate to vigorous physical activity for at least 30 minutes, resulting in a faster-than-normal heart rate, sweating and deep breathing. dDeﬁned as
supplement use for 7 days per week during preceding month. eDeﬁned as three or more pills per week during the past week. fDeﬁned as three or more pills
per week during the past week. Types of NSAIDs included salsalate, diﬂunisal, ibuprofen, ketoprofen, nabumetone, piroxicam, naproxen, diclofenac,
indomethacin, sulindac, tolmetin, etodolac, ketorolac and oxaprozin. gReported cancers include breast cancer, cervical cancer, uterine cancer, lung cancer,
prostate cancer and sarcoma.

supplementation
arm
had
signiﬁcantly
less
weight
gain. Although the overall mean weight change difference
between groups was small (−0.13 kg), women in the active
intervention who had inadequate baseline calcium intakes
(o 1200 mg per day) had 11% lower risks for substantial
weight gain (1–3 kg or 43 kg), whereas those who had calcium
intakes 41200 mg per day were unaffected by treatment
(P for interaction = 0.008).
The vitamin D/calcium trial was imbedded in the other
Women's Health Initiative randomized controlled trials, including
Nutrition & Diabetes (2015) 1 – 7

a diet modiﬁcation trial that may have led to weight loss, thus
inﬂuencing the effects of combined vitamin D/calcium supplementation. It was not possible to differentiate between the effect
of calcium and vitamin D supplementation. Major et al.,29 showed
that among women with calcium intake o 800 mg per day,
calcium and vitamin D supplementation enhanced the beneﬁcial
effect of body weight loss on lipids and lipoprotein proﬁle in over
weight and obese women.
In our study, vitamin D supplementation was not associated
with any signiﬁcant adverse effects. This conﬁrms the

89.63
90.03
201.22
0.41
− 1.05
0.07

17.07
14.23
19.07
− 2.58
4.78
1.83

Weight (wt), kg
Baseline weight
3 month weight
6 month weght
Difference weight (0–3)
Difference weight (3–6)
Difference weight (0–6)

25(OH)D, ng ml − 1
Baseline 25(OH)D
3 month 25(OH)D
6 month 25(OH)D
Difference 25(OH)D(0–3)
Difference 25(OH)D(3–6)
Difference 25(OH)D(0–6)

(1.03)
(0.96)
(1.0)
(0.66)
(0.77)
(0.86)

(2.44)
(2.50)
(5.63)
(0.27)
(0.62)
(0.67)

(0.9)
(0.9)
(0.92)
(0.09)
(0.10)
(0.11)
(2.43)
(2.50)
(5.62)
(0.30)
(0.60)
(0.60 )

(0.91)
(0.93)
(0.96)
(0.11)
(0.10)
(0.16)

17.33 (1.00)
28.12(1.11)
22.26 (0.96)
11.01(1.22)
− 5.80 (1.10)
5.02 (0.87)

89.40
89.29
200.02
− 0.11
− 1.37
− 1.37

32.46
32.41
32.50
− 0.04
− 0.19
− 0.17

81

1000

16.12
35.48
26.77
19.21
− 9.20
10.29

92.73
93.13
203.23
0.39
0.02
0.01

32.96
33.11
32.54
0.15
0.01
0.02

(0.98)
(1.21)
(1.02)
(1.21)
(0.91)
(0.95)

(2.73)
(2.71)
(6.22)
(0.38)
(0.70)
(0.96)

(0.96)
(0.96)
(0.96)
(0.13)
(0.11)
(0.16)

83

2000

17.79
47.30
31.46
29.79
− 15.71
13.81

89.54
89.90
198.48
0.36
− 0.78
− 0.02

32.15
32.28
32.02
0.13
− 0.14
− 0.02

(0.98)
(1.22)
(0.81)
(1.29)
(0.93)
(0.99)

(2.44)
(2.49)
(5.71)
( 0.36)
(0.73)
(0.94)

(0.81)
(0.83)
(0.84)
(0.12)
(0.12)
(0.15)

83

4000

7.75 (0.39)

0.06 (0.24)

0.01 (0.39)

0–3 month change

o0.0001

0.81

0.78

P-value

− 4.74 (0.32)

0.12 (0.22)

0.01 (0.04)

3–6 month change

o0.0001

0.59

0.71

P-value

3.04 (0.31)

0.07 (0.29)

0.01 (0.05)

0–6 month change

o0.0001

0.8

0.87

P-value

Difference BMI (0–3) = month 3 BMI kg m − 2 − month 0 BMI kg m − 2: mean (SE). Difference BMI (3–6) = month 6 BMI kg m − 2 − month 3 BMI kg m − 2: mean (SE). Difference BMI (0–6) = month 6 BMI
kg m − 2 − month 0 BMI kg m − 2: mean (SE). Difference weight (0–3) = month 3 weight, kg − month 0 weight, kg: mean (SE). Difference weight (3–6) = month 6 weight, kg − month 3 weight, kg: mean (SE).
Difference weight (0–6) = month 6 weight, kg − month 0 weight, kg: mean (SE). Difference 25(OH)D(0–3) = month 3, 25(OH)D − month 0, 25(OH)D: mean (SE). Difference 25(OH)D(3–6) = Month 6, 25(OH)
D − month 3, 25(OH)D: mean (SE). Difference 25(OH)D(0–6) = Month 6, 25(OH)D − month 3, 25(OH)D: mean (SE). 0–3 month change in weight, BMI or 25(OH)D per 1000 IU per day of vitamin D supplementation.
3–6 month change in weight, BMI or 25(OH)D per 1000 IU per day of vitamin D supplementation. 0–6 month change in weight, BMI or 25(OH)D per 1000 IU per day of vitamin D supplementation. 25(OH)D
conversion is 2.49 nmol l − 1 for each ng ml −1.

31.85
32.00
32.14
0.15
− 0.18
0

81

BMI, kg m − 2
Baseline BMI
3 month BMI
6 month BMI
Difference BMI (0–3)
Difference BMI (3–6)
Difference BMI (0–6)

n ( at baseline)

Placebo

Effect of vitamin D supplementation on BMI and weight during the treatment (baseline to 3 months, mean (SE)) and 6 months after treatment

Parameter, mean (SE)

Table 2.
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documentation by others that even higher doses of vitamin D3
supplements are safe.30 Strengths of our study include its
prospective design, the use of a double-blind, randomized
placebo-controlled intervention and our adjustment for season.
Another strength is the similarity of living environments of these
urban African-Americans. Relative homogeneity of the population
is likely to reduce the inﬂuence of confounding factors on the
measurement of the vitamin D effect. We considered seasonal
changes in vitamin D and body composition by limiting
supplementation of participants to the winter months.
Limitations of our study include the relatively short duration of
vitamin D supplementation. Yet, this targeted population of obese
African-Americans allowed for short duration and small sample
size with adequate power to test the hypothesis that vitamin D
supplementation reduces BMI. As this was an ancillary analysis, we
did not collect other anthropometric data, such as waist or hip
circumference or arm fat index. Our primary outcome was change
in weight and BMI. These are weaker measures of adiposity than
direct measures. Thus, we may be underestimating the association
between vitamin D supplementation and adiposity.31 Yet, our
ﬁnding agree with other published null ﬁndings of the effects of
vitamin D supplementation on adiposity biomarkers.13 We also
recognize that low dietary calcium intake may have contributed to
our results. This study is unique in that it evaluates vitamin D
supplementation effects in African-Americans with a low intake of
calcium.
Other limitations of the trial compared with some trials
speciﬁcally designed for obesity is the lack of records of energy
intake and detailed measurements of physical activity. Small
changes in BMI may not be detected because of the small
sample size and the measurements of adiposity may not be
sufﬁciently sensitive. BMI includes fat mass, lean mass and
bone mass. Furthermore, a variety of hormones including
gonadal, thyroidal, adrenal and growth hormones inﬂuence
adiposity. These hormones are under the inﬂuence of the
hypothalamic-pituitary axis and have circadian and circannual
rhythms in adults.32 Thus, the association between obesity and
25(OH)D status may be related to other hormones that change
by season.
In conclusion, supplementation with vitamin D did not
signiﬁcantly alter the weight or the BMI over a relatively short
duration in a cohort of overweight or obese African-Americans. It
is not known whether the low serum 25(OH)D in AfricanAmericans is due to vitamin D insufﬁciency secondary to the
increase in fat mass or to other factors such as genotype variation
in vitamin D binding protein or enzymes involved in vitamin D
metabolism. Future trials of longer vitamin D supplementation in
African-Americans are needed to examine the biological contributors to the interaction between vitamin D deﬁciency, obesity,
health disparities and obesity-related chronic diseases.
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